PMID- 18715689
OWN - NLM
STAT- MEDLINE
DCOM- 20081204
LR  - 20081022
IS  - 0301-472X (Print)
IS  - 0301-472X (Linking)
VI  - 36
IP  - 11
DP  - 2008 Nov
TI  - Establishment and characterization of a new human acute myelocytic leukemia cell 
      line SH-2 with a loss of Y chromosome, a derivative chromosome 16 resulting from 
      an unbalanced translocation between chromosomes 16 and 17, monosomy 17, trisomy 
      19, and p53 alteration.
PG  - 1487-95
LID - 10.1016/j.exphem.2008.06.013 [doi]
AB  - OBJECTIVE: To report here a new acute myelocytic leukemia (AML) cell line SH-2 
      and describe its biological characteristics. MATERIALS AND METHODS: Mononuclear 
      cells isolated from a patient with AML-M2 subtype were passaged by liquid culture 
      medium. Interleukin-3 and bone marrow stromal cells were used to support cell 
      proliferation at the first 3 months. Various methods, including cytogenetic 
      analysis, fluorescence in situ hybridization (FISH), multiplex FISH (M-FISH), 
      reverse transcriptase polymerase chain reaction (RT-PCR), multiplex RT-PCR, short 
      tandem repeat (STR)-PCR, direct sequencing of DNA, clonogenic assay, and 
      tumorigenicity in nude and severe combined immunodeficient (SCID) mice were 
      employed to identify and characterize SH-2 cell line. RESULTS: SH-2 cells were 
      maintained without cytokine and stromal cells for 3 years. It had no Epstein-Barr 
      virus or mycoplasma contamination. The SH-2 cell line showed typical myelocytic 
      features in morphology and simultaneous strongly expressed myeloid antigens 
      (CD13, 99.6% and CD33, 99.26%) and natural killer (NK)-related antigens (CD56, 
      99.5% and CD16/56, 99.62%) suggesting that SH-2 is an AML cell line with 
      NK-antigen expression. SH-2 cell line initially showed a karyotype of 45, X, -Y, 
      der(16)t(16;17)(q24;q12), -17, +19. During the passage period, the cells with a 
      hypodiploid karyotype gradually decreased and were replaced by the 
      near-tetraploid cells with a karyotype of 71-105(86), XX, -Y, -Y, 
      der(16)t(16;17)x2, -17, -17, +19, +19. FISH and M-FISH delineated all 
      abnormalities. SH-2 cells had the approximately same morphological, 
      immunophenotypical, and cytogenetic features as the patient's leukemia cells had. 
      STR-PCR provided powerful evidence for the derivation of SH-2 cell line from the 
      patient's leukemia cells. SH-2 cells showed multiple drug resistance (MDR), which 
      may be related to the p53 gene alteration, including the loss of one p53 allele 
      due to the monosomy 17 and a point mutation of CAG to CAT at codon 576 of exon 5 
      in another p53 allele resulting in the loss of p53 gene function. In addition, 
      SH-2 cell line did not express MDR-related genes, such as MDR1, multidrug 
      resistance-related protein, and lung resistance protein, but expressed 
      apoptosis-related genes, such as Bcl-2, Fas, glutathione S-transferase-pi, and 
      p21, which were also related to the MDR. SH-2 cell line had tumorigenic 
      capacities in nude and SCID mice. CONCLUSION: Because SH-2 cell line had a clear 
      biology background, it will provide a useful tool for the study of the 
      pathogenesis and treatment strategy of AML with MDR.
FAU - Qiu, Huiying
AU  - Qiu H
AD  - The First Affiliated Hospital of Soochow University, Jiangsu Institute of 
      Hematology, Key Laboratory of Thrombosis and Hemostasis, Suzhou, P. R. China.
FAU - Xue, Yongquan
AU  - Xue Y
FAU - Zhang, Jun
AU  - Zhang J
FAU - Pan, Jinlan
AU  - Pan J
FAU - Dai, Haiping
AU  - Dai H
FAU - Wu, Yafang
AU  - Wu Y
FAU - Wang, Yong
AU  - Wang Y
FAU - Chen, Suning
AU  - Chen S
FAU - Wu, Depei
AU  - Wu D
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20080819
PL  - Netherlands
TA  - Exp Hematol
JT  - Experimental hematology
JID - 0402313
SB  - IM
MH  - Adult
MH  - *Chromosomes, Human, Pair 16
MH  - *Chromosomes, Human, Pair 17
MH  - *Chromosomes, Human, Pair 19
MH  - *Chromosomes, Human, Y
MH  - *Genes, p53
MH  - Humans
MH  - Immunophenotyping
MH  - In Situ Hybridization, Fluorescence
MH  - Leukemia, Myeloid, Acute/*genetics
MH  - Male
MH  - *Monosomy
MH  - *Translocation, Genetic
MH  - *Trisomy
EDAT- 2008/08/22 09:00
MHDA- 2008/12/17 09:00
CRDT- 2008/08/22 09:00
PHST- 2008/02/28 00:00 [received]
PHST- 2008/06/13 00:00 [revised]
PHST- 2008/06/23 00:00 [accepted]
PHST- 2008/08/22 09:00 [pubmed]
PHST- 2008/12/17 09:00 [medline]
PHST- 2008/08/22 09:00 [entrez]
AID - S0301-472X(08)00309-3 [pii]
AID - 10.1016/j.exphem.2008.06.013 [doi]
PST - ppublish
SO  - Exp Hematol. 2008 Nov;36(11):1487-95. doi: 10.1016/j.exphem.2008.06.013. Epub 
      2008 Aug 19.